AUPH stock information

Sector:

Healthcare

Description:

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Aurinia Pharmaceuticals Inc. website

Current Price

$9.54

RSI

44.14

Market Capitalization:

1.6B

Beta:

1.091

Volume:

1,895,748

Analyst Target Price:

$ 23.81

Economiic Fair Price:

Earnings DateNovember 03, 2022

Report DateNovember 03, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash86.1M

Debt8.2M

EPS-1.265

Profit Margin-253.70 %

Revenue Per Share TTM0.499

Return On Equity TTM-0.411

YoY Revenue Growth (TTM)

704.73 %

YoY Pre Tax Income Growth (TTM)

22.06 %

YoY Free Cash Flow (TTM)

-655.91 %

QoQ Revenue Growth

280.30 %

QoQ Pre Tax Income Growth

84.01 %

QoQ Free Cash Flow Growth

61.89 %

2021 Revenue

$ 45.6M

-9.00 %

2020 Revenue

$ 50.1M

15660.38 %

2019 Revenue

$ 318K

-31.32 %

2018 Revenue

$ 463K

10.24 %

2017 Revenue

$ 420K

142.77 %

2016 Revenue

$ 173K

2021 Free Cash Flow

$ -159.2M

-106.21 %

2020 Free Cash Flow

$ -77.2M

-21.46 %

2019 Free Cash Flow

$ -63.6M

-22.98 %

2018 Free Cash Flow

$ -51.7M

-25.47 %

2017 Free Cash Flow

$ -41.2M

-119.84 %

2016 Free Cash Flow

$ -18.7M

2021 Pre Tax Income

$ -180.2M

-75.34 %

2020 Pre Tax Income

$ -102.8M

16.92 %

2019 Pre Tax Income

$ -123.7M

-93.14 %

2018 Pre Tax Income

$ -64M

9.53 %

2017 Pre Tax Income

$ -70.8M

-203.89 %

2016 Pre Tax Income

$ -23.3M

Aurinia Pharmaceuticals Inc.(AUPH)